Bristol Gets First Mover-Advantage, Again, With Opdivo Kidney Cancer Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s breakthrough approval of Opdivo in second-line metastatic renal cell carcinoma comes on Nov. 23, just one week after filing was accepted.